The Hydroponics Company Limited to be renamed THC Global Group Limited subject to shareholder approval (ASX: THC) Investor Update October 2018
Disclaimer The material in this presentation (material) is not and does not constitute Such statements relate to future events and expectations and, as such, an offer, invitation or recommendation to subscribe for, or purchase any involve known and unknown risks and uncertainties. Actual events and security in The Hydroponics Company Limited (THC) nor does it form the results may differ materially from those expressed or forecasted in basis of any contract or commitment. In the event that an offer, invitation forward-looking statements due to a number of factors. The principal or recommendation to subscribe for, or purchase any security in THC is important risk factors that could cause THC’s actual performance and made in the future, a Prospectus will be made available in relation to the future events and actions to differ materially from such forward-looking same. If and when the Prospectus becomes available it may be statements, include, but are not limited to, continuing volatility in the downloaded from the THC’s website at www.thcl.com.au. At that time capital or credit markets and other changes in the securities and capital any person wishing to make an investment in THC must consider the markets, changes in market prices of THC’s investments, the occurrence Prospectus in deciding whether to acquire the security and must of one or more catastrophic events, such as an earthquake, hurricane, complete the application form that will be in or will accompany the or act of terrorism, changes in laws or regulations, changes in income Prospectus. THC makes no representation or warranty, express or tax laws, and changes in general economic and market factors that implied, as to the accuracy, reliability or completeness of this material. affect the prices of securities or the industries in which it does business. THC, its directors, employees, agents and consultants shall have no This presentation includes certain statements, estimates and projections liability, including liability to any person by reason of negligence or that rely upon various assumptions. Those assumptions may or may not negligent misstatement, for any statements, opinions, information or prove to be correct. The presentation does not purport to contain all the matters, express or implied, arising out of, contained in or derived from, information that a prospective investor may require. The information or for any omissions from this material except liability under statute that may not be appropriate for all persons, and it is not possible for The cannot be excluded. Statements contained in this material, particularly Hydroponics Company Limited to have any regard to the investment those regarding possible or assumed future performance, costs, objectives, financial situation and particular needs of each recipient who dividends, production levels or rates, prices, resources, reserves or reads or uses this information. potential growth of THC, industry growth or other trend projections are, or may be, forward looking statements. 2
Medicinal Cannabis Snapshot R&D including proprietary World Class Growing strains and formulations Facilities & Product exchange with industry Development From ‘ Farm leading global partners Growing capacity of 51,000 Testing and product kg per year of dried flower development laboratory to Pharma ’ Accelerated Access to Medicinal Cannabis Industry-leading large-scale Established international Biopharmaceutical commercial partnerships Manufacturing Facility with global industry ready for pharma-grade leaders across Europe, production Middle East, North America and Australia Extraction capacity of 120,000 kg extract oil per year 3
Corporate Snapshot Core Business THC Global is a diversified global medicinal cannabis business, with a fully vertically integrated ‘ Farm to Pharma ’ medicinal cannabis business across R&D, cultivation, bio-pharmaceutical manufacturing and distribution. THC Global Group Limited Shareholder Metrics Board & Executive Officers Total Shares on Issue (ASX: THC) 126,887,572 Top 20 Holders 37.44% Steven Xu Chairman Total Options on Issue (ASX: THCO) 57,173,024 International Holders % 11.81% Alan Beasley Deputy Chairman Number of Holders 6,183 (750 at IPO) Market Cap (at $0.50) $63.44 million Lou Cattelan Non-Executive Director Cash (30 June 2018) $8.6 million Gary Radcliff Non-Executive Director Corporate Rebranding Ken Charteris Chief Executive Officer Subject to shareholder approval at an EGM to be held 15 November 2018, the Jarrod White Chief Financial Officer name of the Company will change from The Hydroponics Company Limited to Henry Kinstlinger Company Secretary THC Global Group Limited ( THC Global ) The Company will continue trading with the tickers ASX: THC and ASX: THCO 4
Company Milestones Canndeo granted a THC acquires bio- The Hydroponics pharmaceuticals manufacturing Cannabis Research THC signs key commercial First product imported by Company Limited facility including testing and License allowing research partnerships with BOL THC available to (ASX:THC) is product development laboratory of medicinal cannabis Pharma and Endoca Australian Patients Founded AUG 2016 MAY 2017 JUL 2017 OCT 2017 NOV 2017 DEC 2017 APR 2018 MAY 2018 JUL 2018 OCT 2018 EGM called for THC lists on the ASX Canndeo granted a THC commences import THC secures second name change to following a heavily Medicinal Cannabis strategy to service high-capacity THC Global Group oversubscribed $8M Licence allowing domestic patients with medicinal cannabis Limited IPO cultivation and growth commercial partners growing site in NSW and off-take agreements 5
Future Milestones Export and Local Market Expansion Completion of licencing and We look forward to Offtake agreement for permitting activities medicinal cannabis export advising shareholders on existing facilities Medical Trial Development of our progress towards achievement of these milestones Q4 2018 Q1 2019 Q2 2019 over the coming period Expansion of product Revenue generation from Validation of distribution locally manufactured Australian medicinal Steven Xu products cannabis product Chairman from Manufacturing Facility 6
Diversified Cannabis Business THC Global Operating Subsidiaries Canndeo THC Pharma Crystal Mountain Holds R&D and growing facility. Owns THC’s bio -pharmaceutical North American hydroponics equipment manufacturing facility, including a and supplies retailer and distributor. Research and cultivation licences granted. testing and product development Revenue generating operations looking laboratory for full-scale pharma-grade Access to largest Plant Breeder’s Rights (PBR) to expand to cater the burgeoning production and R&D. registered cannabis strain repository in Australia. Canadian micro-LP and home-grow Lease over medicinal cannabis growing market. Distribution of imported cannabis products site in New South Wales, Australia. in Australia. Vertical Canna Inc THC Pharma (NZ) (Canadian Subsidiary to be incorporated) (New Zealand Subsidiary to be incorporated) Marketing and distribution of Marketing and distribution of medicinal, nutraceutical and cannabis products in New Zealand. recreational cannabis products. 7
THC Global Cannabis Capacity THC Globa bal THC Globa bal THC Globa bal THC Globa bal Bio-Pharma rma Queensl sland Northern rn NSW Current Capacity Manufacturi ring Growing g and R&D Growing g Facility Land 4,000 sqm 60,000 sqm 64,000 sqm Greenhou ouses 1,000 sqm 30,000 sqm 31,000sqm Dried Flower r 1,000 kg annually 50,000 kg annually 51,000 kg annually Produ duction on 12,000kg 12,000kg cannabinoid annual cannabinoid annual Extra raction on Capacity extraction equivalent extraction equivalent to to 120,000 kg oil 120,000 kg oil 8
Industry Leading Scalable Bio-Pharmaceutical Manufacturing Capability Production ready facility for large ge scale, pharmaceutical grade GMP manufacturing Capacity to service the domestic market as well Complete vertical as global exportation in growth markets integration from growing to large scale Pharma-grade alcohol/ethanol extraction pharma grade Replacement value +$35 million manufacturing, places THC in an elite global API T echnology capable of extracting all active group of companies. compounds from individual strains Ken Charteris Chief Executive Officer High-capacity to enable processing of plant material from other Australian growers 9
Large Capacity Pharma-Grade Production Monetisation Strategy In Place Annual capacity of 12,000 kg cannabinoid equivalent to 120,000 kg oil production THC is primed and GMP cannabis + GMP manufacturing will ready to deliver enhance attractiveness for product export locally and globally targeted Q2 2019 Ken Charteris Chief Executive Officer Partner off-take agreements in finalisation and others in negotiation T oll manufacturing in addition to own production to monetise capacity Expertise to develop process and formula retained by THC Pharma 10
Testing and Product Development Laboratory Potential to be Australia’s leading cannabis laboratory Our manufacturing site includes a full-scale on-site lab designed for validation of pharma products, testing and R&D Ken Charteris Chief Executive Officer 11
Recommend
More recommend
